More than 1bn people around the world are obese. That means there should be extraordinary demand for drugs to cure or mitigate the condition. Novo Nordisk is now Europe’s most valuable company and Eli Lilly’s market value has more than doubled. Both make the “miracle” drugs that can help people shed up to a fifth of their body weight. But these drugs promise to do more than boost drug companies’ profits. How will they reshape the economy?
Hosts: Alice Fulwood, Mike Bird and Tom Lee-Devlin. Guests: The Economist’s Georgia Banjo; pharmaceuticals analyst Michael Nedelcovych; and John Cawley, a professor of public policy and economics at Cornell University.
Sign up for our new weekly newsletter dissecting the big themes in markets, business and the economy at www.economist.com/moneytalks
Listen to what matters most, from global politics and business to science and technology—subscribe to Economist Podcasts+
For more information about how to access Economist Podcasts+, please visit our FAQs page or watch our video explaining how to link your account.
Hosted on Acast. See acast.com/privacy for more information.
The Intelligence: Going back to raid school
The Intelligence: Dengue’s grip on Latin America
The Intelligence: A civil society in waiting
Checks and Balance: Aid, and a bet
The Intelligence: Britain’s latest bad idea
The Intelligence: The world’s biggest humanitarian crisis
The Intelligence: America’s college crackdowns
The Intelligence: AI rest my case
The Intelligence: Ready, Aid, Fire
The Intelligence: Iran and Israel’s new era?
The Intelligence: Your country needs you!
The Intelligence: He said, she fled
The Intelligence: The most personal choice
The Intelligence: A region holds its breath
The Intelligence: America’s deeply divided electorate
The Intelligence: The race to save Kharkiv
The Intelligence: Can Japan and America Trump-proof their alliance?
Drum Tower: Xi’s doomed economic plan
The Intelligence: Bear up
Create your
podcast in
minutes
It is Free
The Decibel
FT News Briefing
WSJ Tech News Briefing
WSJ What’s News
The World in Brief from The Economist